Stock Events

Third Harmonic Bio 

$12.22
7
-$0.09-0.73% Today

Statistics

Day High
12.43
Day Low
11.99
52W High
16.94
52W Low
5.77
Volume
259,756
Avg. Volume
158,640
Mkt Cap
474.68M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

7
NOV
Earnings
 

Earnings

7NovExpected
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
Q2 2024
Next
-0.43
-0.29
-0.14
0
Expected EPS
-0.29909
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow THRD. It's not an investment recommendation.
Alphabet
77346
GOOGL
Apple
67415
AAPL
Microsoft
62824
MSFT
Amazon
58558
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap127.99B
Vertex Pharmaceuticals is a leader in treating cystic fibrosis, a space where Third Harmonic Bio could potentially compete with its novel anti-inflammatory and autoimmune therapies.
Abbvie
ABBV
Mkt Cap346.75B
AbbVie has a strong portfolio in immunology and oncology, areas that overlap with Third Harmonic Bio's focus on developing treatments for inflammatory diseases.
Regeneron Pharmaceuticals
REGN
Mkt Cap130.59B
Regeneron Pharmaceuticals is involved in developing and commercializing treatments for eye diseases, allergic and inflammatory diseases, which aligns with Third Harmonic Bio's focus areas.
AMGEN
AMGN
Mkt Cap179.38B
Amgen focuses on human therapeutics, including treatments for inflammatory diseases, making it a direct competitor in the biotechnology space where Third Harmonic Bio operates.
Gilead Sciences
GILD
Mkt Cap98.35B
Gilead Sciences is known for its work in antiviral drugs but also has a growing presence in oncology and inflammatory diseases, competing with Third Harmonic Bio's research focus.
Biogen
BIIB
Mkt Cap29.83B
Biogen's portfolio includes treatments for neurological and neurodegenerative diseases, along with research in immunology, potentially competing with Third Harmonic Bio's pipeline.
Novartis
NVS
Mkt Cap244.75B
Novartis is a global healthcare company with a strong emphasis on research and development in pharmaceuticals, including treatments for inflammatory diseases, making it a competitor.
Pfizer
PFE
Mkt Cap164.39B
Pfizer has a broad range of products including anti-inflammatory and autoimmune disease treatments, competing in the same therapeutic areas as Third Harmonic Bio.
Merck
MRK
Mkt Cap300.25B
Merck & Co. is involved in pharmaceuticals including immunology and inflammatory diseases, areas where Third Harmonic Bio is aiming to make an impact.
Johnson & Johnson
JNJ
Mkt Cap399.26B
Johnson & Johnson, through its pharmaceutical segment Janssen, develops treatments for a variety of conditions including inflammatory and autoimmune diseases, competing with Third Harmonic Bio.

Analyst Ratings

20.33$Average Price Target
The highest estimate is $23.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

About

Third Harmonic Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development of the medicine for the treatment of allergic and inflammatory diseases. It develops THB001, an oral small-molecule KIT inhibitor for the treatment of chronic urticaria, a dermatologic disease driven by mast cell activation that results in red, itchy, painful welts, or hives, as well as for airway and gastrointestinal tract indications. The company was formerly known as Project IGE, Inc. and changed its name to Third Harmonic Bio, Inc. in June 2019. Third Harmonic Bio, Inc. was founded in 2019 and is headquartered in Cambridge, Massachusetts.
Show more...
CEO
Employees
42
Country
US
ISIN
US88427A1079

Listings

XNAS
US
THRD